



121

PATENT
ATTORNEY DOCKET NO. 50150/064001

Certificate of Mailing: Date of Deposit: May 25, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kim LaSelva
Printed name of person mailing correspondence

Kim LaSelva
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bernard E. Cabana et al. Art Unit: 1614
Serial No.: 10/668,792 Examiner:
Filed: September 23, 2003 Customer No.: 21559
Title: RIFALAZIL COMPOSITIONS AND THERAPEUTIC REGIMENS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a written opinion from a corresponding international application is also enclosed.

Applicants wish to make known the following copending applications: U.S.S.N. 10/950,917 entitled "Rifalazil Formulations," which was filed on September 27, 2004; and U.S.S.N. 10/948,608 entitled "Regimen for the Administration of Rifamycin-Class Antibiotics" which was filed on September 23, 2004.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

Applicants note that an Information Disclosure Statement and a Form PTO-1449 were filed in this case on January 28, 2004, and that they have not yet received an initialed copy of the Form PTO-1449. Applicants thus request an initialed copy of the Form PTO-1449.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 25 May 2005



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

50150/064001

Serial No.

10/668,792

Applicant

Bernard E. Cabana et al.

Filing Date

September 23, 2003

Group

1614

IDS Filed

May 25, 2005

Customer No.

21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

U.S. PUBLISHED PATENT APPLICATION

Examiner's Initials	Publication Number	Publication Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	20040176404	09/09/04				
	20040126414	07/01/04				

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	"Rifalazil PathoGenesis Plans Phase II Studies," R&D Focus Drug News. June 9, 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.